These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15256332)

  • 21. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teriparatide: A bone formation treatment for osteoporosis.
    Eriksen EF; Robins DA
    Drugs Today (Barc); 2004 Nov; 40(11):935-48. PubMed ID: 15645006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination anabolic and antiresorptive therapy for osteoporosis.
    Cusano NE; Bilezikian JP
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.
    Dede AD; Makras P; Anastasilakis AD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1137-1144. PubMed ID: 28836858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Optimal osteoporosis strategy?].
    Scharla S; Reichenhall B
    Krankenpfl J; 2005; 43(1-3):65. PubMed ID: 15912853
    [No Abstract]   [Full Text] [Related]  

  • 32. [Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2004 Aug; 166(32):2653-5. PubMed ID: 15347166
    [No Abstract]   [Full Text] [Related]  

  • 33. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teriparatide (forteo) for osteoporsis.
    Med Lett Drugs Ther; 2003 Feb; 45(1149):9-10. PubMed ID: 12571538
    [No Abstract]   [Full Text] [Related]  

  • 35. Anabolic agents: what is beyond osteoporosis?
    Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM
    Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on teriparatide in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    BioDrugs; 2009; 23(3):197-9. PubMed ID: 19627171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teriparatide: a review of its use in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    Drugs; 2008; 68(18):2709-37. PubMed ID: 19093708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teriparatide for postmenopausal osteoporosis.
    Drug Ther Bull; 2004 Dec; 42(12):93-5. PubMed ID: 15587764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.